sorafenib-sensitive PDGFR mutants [plasma membrane]

Stable Identifier
R-HSA-9673717
Type
Set [DefinedSet]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
31723821 FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

Smits, S, Appleby, N, Conneally, E, Vandenberghe, P, Michaux, L, Lierman, E

Hemasphere 2019
22665524 Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors

Fletcher, JA, Mariño-Enríquez, A, Heinrich, MC, Donsky, RS, Presnell, A, Griffith, DJ, McKinley, A, Liang, CW, Patterson, J, Taguchi, T

Mol. Cancer Ther. 2012
16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

Marynen, P, Boogaerts, M, Folens, C, Vandenberghe, P, Mentens, N, Scheers, W, Lierman, E, Cools, J, Van Miegroet, H, Stover, EH

Blood 2006
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!